

Philippe Clzardin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7252255/philippe-clezardin-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162
papers

8,268
citations

54
h-index

86
g-index

200
ext. papers

9,112
ext. citations

6.6
avg, IF

6.1
L-index

#	Paper	IF	Citations
162	Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. <i>Cancer Research</i> , 2002 , 62, 6538-44	10.1	377
161	Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. <i>Journal of Clinical Investigation</i> , 2004 , 114, 1714-1725	15.9	317
160	Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 322-30	9.7	204
159	Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. <i>FASEB Journal</i> , 2002 , 16, 1266-8	0.9	202
158	Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. <i>Cancer Research</i> , 2005 , 65, 4971-4	10.1	201
157	SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. <i>Cancer Research</i> , 2003 , 63, 3919-22	10.1	182
156	The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 9643-8	11.5	175
155	Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. <i>Cancer Research</i> , 2007 , 67, 8742-51	10.1	169
154	Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. <i>Journal of Clinical Investigation</i> , 2004 , 114, 1714-25	15.9	168
153	Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. <i>Cancer Research</i> , 2007 , 67, 5821-30	10.1	166
152	Bisphosphonates in cancer therapy. <i>Cancer Letters</i> , 2007 , 257, 16-35	9.9	165
151	A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. <i>Cancer Research</i> , 2007 , 67, 9894-902	10.1	159
150	Effects of bone-targeted agents on cancer progression and mortality. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1059-67	9.7	157
149	Increased Dickkopf-1 expression in breast cancer bone metastases. <i>British Journal of Cancer</i> , 2007 , 97, 964-70	8.7	150
148	Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. <i>PLoS ONE</i> , 2011 , 6, e19234	3.7	136
147	Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. <i>Annals of Oncology</i> , 2016 , 27, 379-90	10.3	135
146	Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. <i>Journal of Bone and Mineral Research</i> , 2001 , 16, 2027-34	6.3	134

145	Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. <i>Cancer Treatment Reviews</i> , 2012 , 38, 407-15	14.4	133
144	Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. <i>Bone</i> , 2011 , 48, 71-9	4.7	129
143	Bone metastasis: pathogenesis and therapeutic implications. <i>Clinical and Experimental Metastasis</i> , 2007 , 24, 599-608	4.7	119
142	High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. <i>Cancer Research</i> , 2011 , 71, 4562-72	10.1	116
141	Interaction of platelet-derived autotaxin with tumor integrin $\alpha 5 \beta 1$ controls metastasis of breast cancer cells to bone. <i>Blood</i> , 2014 , 124, 3141-50	2.2	108
140	The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. <i>Cancer Research</i> , 2011 , 71, 1647-57	10.1	101
139	Metastasis and bone loss: advancing treatment and prevention. <i>Cancer Treatment Reviews</i> , 2010 , 36, 615-20	14.4	100
138	miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes. <i>Cancer Research</i> , 2018 , 78, 5259-5273	10.1	98
137	Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2007 , 101, 135-48	4.4	94
136	Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002 , 25, S3-9	2.7	91
135	Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. <i>Clinical Cancer Research</i> , 2008 , 14, 4658-66	12.9	87
134	Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. <i>PLoS ONE</i> , 2010 , 5, e9741	3.7	87
133	The antitumor potential of bisphosphonates. <i>Seminars in Oncology</i> , 2002 , 29, 33-42	5.5	84
132	Recent insights into the role of integrins in cancer metastasis. <i>Cellular and Molecular Life Sciences</i> , 1998 , 54, 541-8	10.3	83
131	A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers. <i>Thrombosis Research</i> , 1983 , 29, 569-81	8.2	83
130	Therapeutic targets for bone metastases in breast cancer. <i>Breast Cancer Research</i> , 2011 , 13, 207	8.3	80
129	Anti-tumour activity of zoledronic acid. <i>Cancer Treatment Reviews</i> , 2005 , 31 Suppl 3, 1-8	14.4	77
128	Bone metastases. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 83	51.1	77

127	In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. <i>Genes and Development</i> , 2001 , 15, 1373-82	12.6	76
126	International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. <i>European Journal of Cancer</i> , 2007 , 43, 852-8	7.5	74
125	Complex formation of human thrombospondin with osteonectin. <i>FEBS Journal</i> , 1988 , 175, 275-84		74
124	TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E3870-9	11.5	73
123	Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain 1999 , 75, 538-546		73
122	Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. <i>Oncogene</i> , 2013 , 32, 724-35	9.2	72
121	Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. <i>Bone</i> , 2011 , 48, 259-66	4.7	72
120	Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. <i>Journal of Biological Chemistry</i> , 2003 , 278, 45826-32	5.4	71
119	Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. <i>International Journal of Cancer</i> , 1999 , 83, 263-9	7.5	70
118	In vitro and in vivo antitumor effects of bisphosphonates. <i>Current Medicinal Chemistry</i> , 2003 , 10, 173-80	4.3	68
117	One-step procedure for the rapid isolation of mouse monoclonal antibodies and their antigen binding fragments by fast protein liquid chromatography on a mono Q anion-exchange column. <i>Journal of Chromatography A</i> , 1985 , 319, 67-77	4.5	68
116	Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. <i>International Journal of Cancer</i> , 2011 , 128, 352-60	7.5	65
115	Cathepsin K inhibitors as treatment of bone metastasis. <i>Current Opinion in Supportive and Palliative Care</i> , 2008 , 2, 218-22	2.6	61
114	Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. <i>British Journal of Cancer</i> , 2012 , 107, 63-70	8.7	60
113	Dual function of ERR α in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. <i>Cancer Research</i> , 2011 , 71, 5728-38	10.1	59
112	Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. <i>Journal of Cellular Biochemistry</i> , 1997 , 67, 75-83	4.7	59
111	Cancer Cell Colonisation in the Bone Microenvironment. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	59
110	Bone-Targeted Therapies in Cancer-Induced Bone Disease. <i>Calcified Tissue International</i> , 2018 , 102, 227-350	3.9	58

109	Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. <i>BoneKEy Reports</i> , 2013 , 2, 267		56
108	TWIST1 expression in breast cancer cells facilitates bone metastasis formation. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 1886-99	6.3	54
107	How do bisphosphonates inhibit bone metastasis in vivo?. <i>Neoplasia</i> , 2010 , 12, 571-8	6.4	54
106	Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis. <i>British Journal of Haematology</i> , 1985 , 60, 331-44	4.5	52
105	Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. <i>Cancer Research</i> , 2005 , 65, 300-8	10.1	52
104	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. <i>International Journal of Cancer</i> , 2005 , 116, 686-91	7.5	51
103	Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. <i>International Journal of Oncology</i> , 2012 , 40, 1133-41	4.4	49
102	The role of osteoclasts in breast cancer bone metastasis. <i>Journal of Bone Oncology</i> , 2016 , 5, 93-95	4.5	48
101	Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. <i>Prostate</i> , 2012 , 72, 713-20	4.2	47
100	Bisphosphonates in preclinical bone oncology. <i>Bone</i> , 2011 , 49, 66-70	4.7	46
99	P49. Zoledronic acid-induced IPP accumulation in cancer cells strongly correlates with T-cell mediated cancer cell death. <i>Cancer Treatment Reviews</i> , 2008 , 34, 37	14.4	46
98	The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. <i>Oncotarget</i> , 2015 , 6, 20604-20	3.3	46
97	Thrombospondin is synthesized and secreted by human osteoblasts and osteosarcoma cells. A model to study the different effects of thrombospondin in cell adhesion. <i>FEBS Journal</i> , 1989 , 181, 721-6		45
96	Lysyl Oxidase Is a Strong Determinant of Tumor Cell Colonization in Bone. <i>Cancer Research</i> , 2017 , 77, 268-278	10.1	44
95	Advances in optical imaging and novel model systems for cancer metastasis research. <i>Clinical and Experimental Metastasis</i> , 2007 , 24, 699-705	4.7	44
94	Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2009 , 145, 264-6	4.5	42
93	In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger VβVβ T-cell antitumor cytotoxicity through ICAM-1 engagement. <i>Clinical Cancer Research</i> , 2012 , 18, 6249-59	12.9	41
92	Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. <i>Cancer Research</i> , 2008 , 68, 8945-53	10.1	39

91	Isolation of thrombospondin released from thrombin-stimulated human platelets by fast protein liquid chromatography on an anion-exchange Mono-Q column. <i>Journal of Chromatography A</i> , 1984 , 296, 249-56	4.5	39
90	The molecular basis of bisphosphonate activity: a preclinical perspective. <i>Seminars in Oncology</i> , 2010 , 37 Suppl 1, S3-11	5.5	35
89	Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. <i>Journal of Biological Chemistry</i> , 2014 , 289, 6551-6564	5.4	34
88	Nanostructured polyelectrolyte multilayer drug delivery systems for bone metastasis prevention. <i>Biomaterials</i> , 2009 , 30, 6367-73	15.6	34
87	Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms. <i>Oncology Research</i> , 2009 , 18, 173-84	4.8	33
86	Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. <i>Anticancer Research</i> , 2012 , 32, 5211-20	2.3	33
85	Integrins in bone metastasis formation and potential therapeutic implications. <i>Current Cancer Drug Targets</i> , 2009 , 9, 801-6	2.8	32
84	Tumour-derived miRNAs and bone metastasis. <i>BoneKEy Reports</i> , 2015 , 4, 688		31
83	Transmigration: a new property of mature multinucleated osteoclasts. <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 1913-23	6.3	31
82	Nitrogen-containing bisphosphonates and cancer immunotherapy. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3007-2014	3.3	30
81	Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. <i>Bone</i> , 2018 , 108, 202-209	4.7	29
80	Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1. <i>Biochemical Journal</i> , 1997 , 321 (Pt 3), 819-27	3.8	28
79	Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. <i>Neoplasia</i> , 2008 , 10, 1014-20	6.4	28
78	A convenient clinically relevant model of human breast cancer bone metastasis. <i>Clinical and Experimental Metastasis</i> , 2008 , 25, 33-42	4.7	28
77	Characterization of two murine monoclonal antibodies (P10, P12) directed against different determinants on human blood platelet thrombospondin. <i>FEBS Journal</i> , 1986 , 154, 95-102		28
76	Pathophysiology of bone metastases from solid malignancies. <i>Joint Bone Spine</i> , 2017 , 84, 677-684	2.9	27
75	Emerging therapies in bone metastasis. <i>Current Opinion in Pharmacology</i> , 2015 , 22, 79-86	5.1	25
74	A transcriptome-proteome integrated network identifies endoplasmic reticulum thiol oxidoreductase (ERp57) as a hub that mediates bone metastasis. <i>Molecular and Cellular Proteomics</i> , 2013 , 12, 2111-25	7.6	25

73	Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. <i>Prostate</i> , 2013 , 73, 1738-46	4.2	25
72	Bone metastasis: mechanisms, therapies, and biomarkers. <i>Physiological Reviews</i> , 2021 , 101, 797-855	47.9	25
71	Potential anticancer properties of bisphosphonates: insights from preclinical studies. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012 , 12, 102-13	2.2	24
70	Osteonectin is an alpha-granule component involved with thrombospondin in platelet aggregation. <i>Journal of Bone and Mineral Research</i> , 1991 , 6, 1059-70	6.3	23
69	A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. <i>PLoS ONE</i> , 2013 , 8, e75092	3.7	21
68	Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice. <i>Calcified Tissue International</i> , 2010 , 87, 341-50	3.9	21
67	Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone. <i>Oncotarget</i> , 2016 , 7, 77071-77086	3.3	21
66	Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). <i>BoneKEy Reports</i> , 2014 , 3, 580		20
65	Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis. <i>Journal of Proteome Research</i> , 2012 , 11, 2247-60	5.6	19
64	Structural and immunological comparison of human thrombospondins isolated from platelets and from culture supernatants of endothelial cells and fibroblasts. Evidence for a thrombospondin polymorphism. <i>FEBS Journal</i> , 1986 , 159, 569-79		19
63	Thrombospondin in milk, other breast secretions, and breast tissue. <i>Seminars in Thrombosis and Hemostasis</i> , 1987 , 13, 378-84	5.3	19
62	ERR β promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. <i>Oncogene</i> , 2019 , 38, 950-964	9.2	19
61	Expression and localisation of alphav integrins in human odontoblasts. <i>Cell and Tissue Research</i> , 2006 , 323, 457-63	4.2	18
60	Tandem purification of IgM monoclonal antibodies from mouse ascites fluids by anion-exchange and gel fast protein liquid chromatography. <i>Journal of Chromatography A</i> , 1986 , 354, 425-33	4.5	18
59	Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation. <i>Oncotarget</i> , 2017 , 8, 56460-56472	3.3	18
58	Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers. <i>PLoS ONE</i> , 2014 , 9, e97771	3.7	17
57	Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. <i>International Journal of Cancer</i> , 2014 , 135, 1319-29	7.5	17
56	The RANK-RANKL axis: an opportunity for drug repurposing in cancer?. <i>Clinical and Translational Oncology</i> , 2019 , 21, 977-991	3.6	16

55	Low-Intensity Ultrasound Promotes Clathrin-Dependent Endocytosis for Drug Penetration into Tumor Cells. <i>Ultrasound in Medicine and Biology</i> , 2015 , 41, 2740-54	3.5	16
54	CD36 mediates binding of soluble thrombospondin-1 but not cell adhesion and haptotaxis on immobilized thrombospondin-1. <i>Cell Biochemistry and Function</i> , 1998 , 16, 211-21	4.2	16
53	Thrombospondin (TSP1) mediates in vitro proliferation of human MG-63 osteoblastic cells induced by alpha-thrombin. <i>FEBS Letters</i> , 1993 , 329, 341-6	3.8	16
52	Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. <i>Oncogene</i> , 2021 , 40, 1284-1299	9.2	16
51	Unseeded Inertial Cavitation for Enhancing the Delivery of Chemotherapies: A Safety Study. <i>Ultrasound in Medicine and Biology</i> , 2016 , 42, 220-31	3.5	15
50	Identification and characterization of fragments of major glycoproteins from platelet membrane after chymotrypsin treatment. <i>FEBS Journal</i> , 1985 , 148, 97-106		15
49	The CaSR in Pathogenesis of Breast Cancer: A New Target for Early Stage Bone Metastases. <i>Frontiers in Oncology</i> , 2020 , 10, 69	5.3	14
48	Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1. <i>Journal of Bone and Mineral Research</i> , 2000 , 15, 361-8	6.3	14
47	Non-coding RNAs in bone remodelling and bone metastasis: Mechanisms of action and translational relevance. <i>British Journal of Pharmacology</i> , 2021 , 178, 1936-1954	8.6	14
46	Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer. <i>Scientific Reports</i> , 2015 , 5, 16354	4.9	13
45	Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. <i>BoneKEy Reports</i> , 2015 , 4, 744		12
44	Tryptic peptide map analysis of the major human blood platelet membrane glycoproteins separated by two-dimensional polyacrylamide gel electrophoresis. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1982 , 689, 513-22	3.8	12
43	TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases. <i>Cancer Letters</i> , 2018 , 438, 32-43	9.9	12
42	Tandem purification of mouse IgM monoclonal antibodies produced in vitro using anion-exchange and gel fast protein liquid chromatography. <i>Journal of Chromatography A</i> , 1986 , 358, 209-18	4.5	11
41	Tandem separation of labelled human blood platelet membrane glycoproteins by anion-exchange and gel fast protein liquid chromatography. <i>Journal of Chromatography A</i> , 1985 , 326, 179-90	4.5	10
40	The growth-supportive effect of thrombospondin (TSP1) and the expression of TSP1 by human MG-63 osteoblastic cells are both inhibited by dexamethasone. <i>FEBS Letters</i> , 1993 , 335, 161-6	3.8	9
39	The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis. <i>Calcified Tissue International</i> , 2018 , 103, 567-580	3.9	9
38	Localization of thrombospondin, CD36 and CD51 during prenatal development of the human mammary gland. <i>Differentiation</i> , 1994 , 57, 133-41	3.5	8

37	Cell attachment and fibrinogen binding properties of platelet and endothelial cell thrombospondin are not affected by structural differences in the 70 and 18 kDa protease-resistant domains. <i>FEBS Letters</i> , 1988 , 228, 215-8	3.8	7
36	Bone metastases in the era of targeted treatments: insights from molecular biology. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 63, 98-111	1.4	7
35	ERR α Expression in Bone Metastases Leads to an Exacerbated Antitumor Immune Response. <i>Cancer Research</i> , 2020 , 80, 2914-2926	10.1	6
34	Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study. <i>Clinical Breast Cancer</i> , 2018 , 18, e1311-e1321	3	6
33	Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGF β /CTGF Axis. <i>Cells</i> , 2021 , 10,	7.9	6
32	Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced V β V α T cell cytotoxicity in PC-3 prostate cancer cells. <i>Cancer Letters</i> , 2015 , 357, 279-285	9.9	5
31	Insights into the antitumor effects of bisphosphonates from preclinical models and potential clinical implications. <i>IBMS BoneKEy</i> , 2009 , 6, 210-217		4
30	Production, characterization, and use of monoclonal antibodies directed against human blood platelet thrombospondin: immunologic comparison with human endothelial and fibroblast thrombospondins. <i>Seminars in Thrombosis and Hemostasis</i> , 1987 , 13, 261-75	5.3	4
29	MicroRNA-mediated regulation of bone metastasis formation: from primary tumors to skeleton 2015 , 479-489		3
28	Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay. <i>Frontiers in Oncology</i> , 2020 , 10, 712	5.3	3
27	Structural and immunological differences between human platelet and endothelial thrombospondins. <i>FEBS Letters</i> , 1986 , 196, 49-53	3.8	3
26	MicroRNAs and Their Roles in Breast Cancer Bone Metastasis. <i>Current Osteoporosis Reports</i> , 2021 , 19, 256-263	5.4	3
25	Os, cible thérapeutique (RPC 2013). <i>Oncologie</i> , 2013 , 15, 673-686	1	2
24	Effect of intra-tibial injection on mechanical properties of mouse bone. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2017 , 20, 57-58	2.1	2
23	1074 POSTER Effects of Zoledronic Acid and Denosumab on Human Vy9V62 T-cell-Mediated Cell Death of RANK-Expressing Breast Cancer Cells. <i>European Journal of Cancer</i> , 2011 , 47, S117	7.5	2
22	Early Bone Metastasis-Associated Molecular and Cellular Events 2010 , 41-45		2
21	Frequent low-dose bisphosphonate therapy. <i>Bone</i> , 2007 , 41, 901-2	4.7	2
20	Pourquoi certains cancers métastasent-ils préférentiellement dans les Os ?. <i>Oncologie</i> , 2012 , 14, 31-36	1	1

19	RANK/RANKL pathway in cancer: Biological activity beyond bone?. <i>Journal of Bone Oncology</i> , 2012 , 1, 67-8	4.5	1
18	Can bisphosphonates really reduce the risk of recurrences in early breast cancer?. <i>IBMS BoneKEy</i> , 2011 , 8, 159-164		1
17	Fracture Risk Evaluation of Bone Metastases: A Burning Issue. <i>Cancers</i> , 2021 , 13,	6.6	1
16	Physiopathologie des m�astases osseuses des tumeurs solides. <i>Revue Du Rhumatisme Monographies</i> , 2017 , 84, 107-114	0	0
15	Physiopathologie des m�astases osseuses. <i>Oncologie</i> , 2015 , 17, 69-74	1	
14	Physiopathologie des m�astases osseuses. <i>Oncologie</i> , 2009 , 11, 10-15	1	
13	Clinical and basic research papers [February 2011. <i>IBMS BoneKEy</i> , 2011 , 8, 65-73		
12	Clinical and basic research papers [July 2011. <i>IBMS BoneKEy</i> , 2011 , 8, 305-312		
11	Clinical and basic research papers [November-December 2011. <i>IBMS BoneKEy</i> , 2011 , 8, 305-312		
10	Clinical and basic research papers [September 2011. <i>IBMS BoneKEy</i> , 2011 , 8, 390-396		
9	Clinical and basic research papers [October 2011. <i>IBMS BoneKEy</i> , 2011 , 8, 428-432		
8	Bioluminescence imaging of prenylation inhibition--letter. <i>Clinical Cancer Research</i> , 2012 , 18, 6077; author reply 6078	12.9	
7	Pathog�ie des m�astases osseuses. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2008 , 75, 327-331	0.1	
6	Antitumour Effects of Bisphosphonates 2006 , 345-350		
5	Activit� anti-tumorale des bisphosphonates: mythe ou r�alit�. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2002 , 69, 997-1001	0.1	
4	M�canismes d'action des bisphosphonates sur les cellules tumorales et perspectives d'utilisation dans le traitement de l'ost�olyse maligne. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2000 , 67, 28-36	0.1	
3	Current and Emerging Bone-Targeted Therapies for The Treatment of Bone Metastases From Solid Tumors 2020 , 403-420		
2	Bone Metastases; Basic Aspects 2019 , 304-309		

- 1 MicroRNAs and bone metastasis **2022**, 457-469